Skip To Main Content
Madison Roberts on Muck Rack

Madison Roberts

North Carolina
As seen in: Condé Nast Traveler, Elba Clipper, Medium, MSN, MSN Canada, MSN Singapore, Yahoo Entertainment, Yahoo Life, MSN South Africa, Yahoo Canada, Aol and
Freelance Food & Travel Writer | Words @cntraveler @people @thekitchn @cosmopolitan | #EndAlz and @pancan supporter | Opinions are my own
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Madison

Contact Madison, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Psychedelic Medicine Is Having an Identity Crisis — And That’s a Good Thing

|
By Madison Roberts
| Microdose Psychedelic Insights
For most of the last decade, the story of psychedelic medicine was a story about the trip itself. Guided sessions. Eyeshades and headphones. A therapist sitting with a patient for six or eight hours while a single dose of psilocybin or MDMA did its work. That was the model — expensive, logistically heavy, and philosophically tied to the idea that the altered state of consciousness was the medicine. Walking into the second half of 2026, that’s no longer the whole industry.
Open in Who Shared Issue with article?

Enveric Biosciences Adds Another Data Point to Its Case That EB-003 Won’t Get You High

|
By Madison Roberts
| Microdose Psychedelic Insights
Enveric Biosciences is trying to answer one of the trickiest questions in the psychedelic drug space: can you get the antidepressant benefits people associate with psychedelics without the trip? On August 5, 2026, the Cambridge, Massachusetts-based biotech (NASDAQ: ENVB) released new preclinical data it says strengthens the argument that its lead candidate, EB-003, can do exactly that.
Open in Who Shared Issue with article?

FDA’s New Psychedelic Guidance Signals a Maturing Industry. Now Comes the Hard Part.

|
By Madison Roberts
| Microdose Psychedelic Insights
For years, the psychedelic medicine industry has operated in largely uncharted regulatory territory. Companies developing psilocybin, LSD, MDMA, and next-generation psychedelic-inspired compounds have often found themselves navigating a clinical landscape with few precedents and even fewer roadmaps. While excitement surrounding the therapeutic potential of these compounds has accelerated, the regulatory framework has struggled to keep pace. That dynamic may finally be changing.
Open in Who Shared Issue with article?
See all 3,131 licensed articles (3,145 Total)